Free Trial

Generation Bio (GBIO) Competitors

Generation Bio logo
$6.45 +0.17 (+2.71%)
Closing price 04:00 PM Eastern
Extended Trading
$6.54 +0.09 (+1.32%)
As of 07:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GBIO vs. CYBN, ACTU, NKTX, NVCT, BIOA, GLSI, CRDF, DERM, CLLS, and MEIP

Should you be buying Generation Bio stock or one of its competitors? The main competitors of Generation Bio include Cybin (CYBN), Actuate Therapeutics (ACTU), Nkarta (NKTX), Nuvectis Pharma (NVCT), BioAge Labs (BIOA), Greenwich LifeSciences (GLSI), Cardiff Oncology (CRDF), Journey Medical (DERM), Cellectis (CLLS), and MEI Pharma (MEIP). These companies are all part of the "pharmaceutical products" industry.

Generation Bio vs. Its Competitors

Cybin (NYSE:CYBN) and Generation Bio (NASDAQ:GBIO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, media sentiment, earnings, analyst recommendations and dividends.

Cybin has a net margin of 0.00% compared to Generation Bio's net margin of -341.12%. Cybin's return on equity of -37.58% beat Generation Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
CybinN/A -37.58% -36.59%
Generation Bio -341.12%-91.07%-33.65%

Cybin has higher earnings, but lower revenue than Generation Bio. Cybin is trading at a lower price-to-earnings ratio than Generation Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CybinN/AN/A-$57.88M-$4.60-1.55
Generation Bio$19.89M2.19-$131.67M-$10.82-0.60

Cybin has a beta of 0.68, suggesting that its stock price is 32% less volatile than the S&P 500. Comparatively, Generation Bio has a beta of 2.67, suggesting that its stock price is 167% more volatile than the S&P 500.

17.9% of Cybin shares are held by institutional investors. Comparatively, 95.2% of Generation Bio shares are held by institutional investors. 15.0% of Cybin shares are held by company insiders. Comparatively, 21.8% of Generation Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Cybin had 11 more articles in the media than Generation Bio. MarketBeat recorded 17 mentions for Cybin and 6 mentions for Generation Bio. Cybin's average media sentiment score of 0.09 beat Generation Bio's score of -0.25 indicating that Cybin is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cybin
3 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Generation Bio
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Cybin presently has a consensus target price of $85.00, suggesting a potential upside of 1,088.81%. Generation Bio has a consensus target price of $10.67, suggesting a potential upside of 65.37%. Given Cybin's stronger consensus rating and higher possible upside, analysts clearly believe Cybin is more favorable than Generation Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cybin
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
3.25
Generation Bio
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67

Summary

Cybin beats Generation Bio on 10 of the 16 factors compared between the two stocks.

Get Generation Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for GBIO and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GBIO vs. The Competition

MetricGeneration BioMED IndustryMedical SectorNASDAQ Exchange
Market Cap$43.47M$3.09B$5.82B$9.74B
Dividend YieldN/A2.23%3.84%4.09%
P/E Ratio-0.6021.1431.1525.97
Price / Sales2.19399.83475.57123.18
Price / CashN/A43.0937.1558.38
Price / Book0.808.079.116.39
Net Income-$131.67M-$54.72M$3.26B$265.66M
7 Day Performance2.54%2.62%2.11%1.98%
1 Month Performance51.05%7.63%5.12%1.33%
1 Year Performance-74.40%13.11%31.25%21.15%

Generation Bio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GBIO
Generation Bio
3.2301 of 5 stars
$6.45
+2.7%
$10.67
+65.4%
-75.8%$43.47M$19.89M-0.60150
CYBN
Cybin
2.5222 of 5 stars
$6.92
-2.0%
$85.00
+1,128.3%
N/A$166.55MN/A-1.5850News Coverage
Analyst Revision
ACTU
Actuate Therapeutics
N/A$8.25
+1.6%
$20.50
+148.5%
-10.9%$166.22MN/A0.0010News Coverage
Analyst Revision
NKTX
Nkarta
2.0708 of 5 stars
$2.35
+0.9%
$13.60
+478.7%
-56.9%$165.49MN/A-1.59140
NVCT
Nuvectis Pharma
3.8378 of 5 stars
$6.45
+0.3%
$15.33
+137.7%
-11.3%$163.69MN/A-5.518Positive News
BIOA
BioAge Labs
N/A$4.52
-0.7%
N/AN/A$163.12M$3.86M0.00N/A
GLSI
Greenwich LifeSciences
1.4633 of 5 stars
$12.01
-1.3%
$39.00
+224.7%
-19.9%$162.69MN/A-8.833Trending News
Analyst Forecast
Analyst Revision
CRDF
Cardiff Oncology
1.6497 of 5 stars
$2.43
-0.4%
$10.10
+315.6%
-3.0%$162.32M$680K-2.7920
DERM
Journey Medical
1.6736 of 5 stars
$7.00
+0.7%
$10.83
+54.8%
+60.9%$161.91M$56.13M-18.4290
CLLS
Cellectis
3.3874 of 5 stars
$2.90
+1.8%
$4.00
+37.9%
+17.6%$158.41M$49.22M-3.54290Positive News
Short Interest ↓
MEIP
MEI Pharma
1.3625 of 5 stars
$4.88
-0.2%
N/A+47.1%$158.28M$65.30M-1.03100

Related Companies and Tools


This page (NASDAQ:GBIO) was last updated on 8/22/2025 by MarketBeat.com Staff
From Our Partners